Paclitaxel-induced sickle cell crisis.
OBJECTIVE
A case of paclitaxel-induced painful crisis in a patient with breast cancer and hemoglobin sickle cell disease (SCD) is reported.


CONCLUSIONS
A 55-year-old postmenopausal African-American woman had stage IIB invasive ductal carcinoma of the left breast. She was not taking any medications and did not report a history of cancer or other diseases. She had mild microcytic anemia, but the rest of her blood counts and liver function test values were normal. Bone scans and computed tomography scans of her chest and abdomen did not reveal any metastatic disease. She underwent a routine left segmental mastectomy and axillary lymph node dissection that revealed a 4-cm invasive cancer with 1 of 10 axillary lymph nodes positive for metastatic disease. Her treatment plan included chemotherapy with weekly paclitaxel, followed by fluorouracil, epirubicin, and cyclophosphamide and radiation. The first cycle of paclitaxel was well tolerated until one week after initiation when the patient woke up in the middle of the night with a sudden onset of excruciating back pain and muscle spasms. Other symptoms that developed included fatigue, left-sided rib pain, and shortness of breath. The patient recalled being told that she had sickle cell trait but said that she never had a sickle cell crisis. Laboratory tests during her 13-day hospitalization revealed hemolysis. The patient was diagnosed with hemoglobin SCD and later discharged with as-needed, low-dose oxycodone and baclofen, antibiotics, and folic acid.


CONCLUSIONS
A patient with breast cancer and SCD had a painful crisis after receiving paclitaxel as part of her chemotherapy regimen.
Wilson
Nicole M
NM
Butler University College of Pharmacy and Health Sciences, Indianapolis, IN, USA. nmwilson@butler.edu [corrected]
Espirito
Janet L
JL
Valero
Vicente
V
Pusztai
Lajos
L
D001741:Black or African American; D000755:Anemia, Sickle Cell; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage / Q000009:adverse effects* / Q000494:pharmacology; D001943:Breast Neoplasms / Q000188:drug therapy; D005260:Female; D006801:Humans; D008875:Middle Aged; D017239:Paclitaxel / Q000008:administration & dosage / Q000009:adverse effects* / Q000494:pharmacology; D010146:Pain / Q000139:chemically induced*
D000972:Antineoplastic Agents, Phytogenic; D017239:Paclitaxel